Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Fig. 4

4A, PFS according to ECOG PS classes; 4B, OS according to ECOG PS classes; 4C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4E, PFS in patients treated with pembrolizumab monotherapy according to ECOG PS classes; 4F, OS in patients treated with pembrolizumab monotherapy according to ECOG PS classes

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us